Trial Profile
A Randomized, Double-blind, Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COV2.S Administered As a Two-Dose Schedule in Healthy Adults
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs Ad26.COV2 S (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics; Registrational
- Sponsors Janssen Vaccines and Prevention B.V
- 11 Sep 2023 Last checked against European Clinical Trials Database record.
- 08 Sep 2023 This trial has been completed in Germany and Poland (Date of the global end of the trial: 10-Jul-2023), according to the European Clinical Trials Database record.
- 11 Apr 2023 Planned End Date changed from 28 Dec 2023 to 14 Jul 2023.